Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
about
Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitusEffect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism.Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes.Glycated haemoglobin in the year 2000.Metabolic remodeling of white adipose tissue in obesityBeyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.Impact of nutrient excess and endothelial nitric oxide synthase on the plasma metabolite profile in mice.1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate CombinationThe interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoringSerum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction.A systems view of type 2 diabetes-associated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic controlPlasma metabolomic profiles enhance precision medicine for volunteers of normal health.Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Alternative markers of hyperglycemia and risk of diabetes.Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease.Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young.Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assayLow and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention.Glycemic control indicators in patients with neonatal diabetes mellitus.Metabolomics in human type 2 diabetes research.A computational model of 1,5-AG dynamics during pregnancy.Insulin induces a shift in lipid and primary carbon metabolites in a model of fasting-induced insulin resistance.Key elements of metabolomics in the study of biomarkers of diabetes.1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions.Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes.Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular DiseaseRepeated 3-minute stair climbing-descending exercise after a meal over 2 weeks increases serum 1,5-anhydroglucitol levels in people with type 2 diabetes.Detection of 1,5-Anhydroglucitol by Electrochemical Impedance SpectroscopySerum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes.Clinical application of the serum 1,5-anhydroglucitol assay method using glucose 3-dehydrogenase.Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0.High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus.Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin.Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
P2860
Q26799252-509A2B31-14DD-42A1-8239-7979EFCF235FQ33585892-9ED0BECE-FBB6-44DC-9318-0E1A6D0A199FQ33784296-F15AA802-99F1-44C6-8133-54C9F1BFB09EQ33964851-547613BF-CB40-43A0-985F-973F5C9639B7Q34001327-772814D6-5392-4B6E-9A2E-4AAE08AA8B6BQ34425731-4F20C6ED-D493-4CC3-B4A2-2872D591FDC1Q34433155-D6BE6FEA-6465-41EC-93FD-5A3E5C084DAFQ34569354-4B032040-F45A-430B-97E5-ABB084864171Q34726941-036D8286-500C-4ADC-A5AF-9396956AEDC7Q35192184-C1E0B8C1-9692-4D29-A790-8D4E47ABD076Q35349795-837831DC-EEA6-4904-AE44-7699A4C04013Q35688303-409F1ABD-C756-4B87-8026-A1C26D7C6BDCQ35842441-95260BB7-C6AE-4B47-BADD-9360852BAB26Q36055457-F94BC1BD-C49C-4C97-9827-9ED638113EB7Q36194286-DEA85D86-39D7-41FC-97AB-C965AE6738B5Q36237217-BA55506E-9F32-471C-B6AA-07A68ACC7706Q36334628-753FC9F0-4B48-4B10-AAB8-0762381E6081Q36686926-BA884371-E6D9-4961-8A7D-4157FF0DBD79Q36726169-25BD75AB-91BC-4FCF-A819-8D4DD08C8DFBQ36807529-1AFDB6DB-90BA-48DB-A8BB-194E581E6A1AQ36900001-003B5954-E372-4CBB-AE28-5308CDCF1812Q36911219-94825904-6A81-4F4B-8B4C-707C118608F7Q37326200-494985D3-1978-48AF-B765-D8F6D7822D61Q37708623-8B338BC0-220F-4848-9C06-7837A323A823Q38078841-F4E368C8-7DFC-4C98-8C97-588066D9EA19Q38618027-1653A119-FF6C-4F8B-BB7A-E87B91D3D56CQ38693344-41C4C2A9-95CC-4B76-8956-400577916811Q38974645-E8CEC097-259F-4C1C-BF5B-EFDAA2AE041BQ39717154-75E1C7CF-B2B5-42CE-9FF5-B7A0DCDE7544Q40452129-12623BB8-54A0-4A32-AA06-99182D317C37Q41640157-29A958D4-1225-4D7A-883C-E356322812EEQ42322661-FFEA7861-DC0D-48DC-8403-4A124DE9ECEBQ42723825-AC55BB60-620F-4423-80A4-8C635C0E45EEQ43857832-E70E2D8C-0CFF-4A85-A119-C4FE21C93BC3Q44211490-9D77379F-562C-4FCD-8A24-9B10EAB3692BQ46960793-6E87B4B5-E44E-4563-8F7B-AF5CF27F2D77Q47963224-EE2E1303-6EC7-472C-8D30-B665AEE2E962Q50871216-4D936ABB-0586-43AA-B719-1CC7A7F0347CQ51011452-E974A877-E6B5-4944-8CB4-87E47A25329FQ51052616-6DCC00B8-24BD-4CD3-9C48-183BE11DB831
P2860
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@ast
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@en
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@nl
type
label
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@ast
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@en
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@nl
prefLabel
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@ast
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@en
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@nl
P2093
P1433
P1476
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
@en
P2093
H Miyashita
T Kawasaki
T Yamanouchi
P304
P356
10.1016/S0140-6736(96)90672-8
P407
P577
1996-06-01T00:00:00Z